Comparison of paroxetine and dapoxetine, a novel selective serotonin reuptake inhibitor in the treatment of premature ejaculation

Abstract

Dapoxetine hydrochloride is a selective serotonin reuptake inhibitor and the first drug approved for the on-demand treatment of premature ejaculation (PE). Our objective in this study was to characterize the efficacy of on-demand dapoxetine (30 and 60 mg) and daily paroxetine (20 mg) usage in treating PE. We conducted a 1 month study involving a total of 150 patients. Patients were divided into three groups of 50. Group 1 were treated with on-demand dapoxetine (30 mg), Group 2 with on-demand dapoxetine (60 mg) and Group 3 with daily paroxetine (20 mg). Our outcome measurement was increased from baseline intravaginal ejaculatory latency time (IELT) after treatment. The IELT increased from baseline to posttreatment by 117%, 117% and 170% in the paroxetine group (P < 0.01), 30 mg dapoxetine group (P < 0.01) and 60 mg dapoxetine group (P < 0.01), respectively. The increase from baseline IELT were similar for the 30 mg dapoxetine and paroxetine groups (P > 0.05), while the 60 mg dapoxetine group had a larger posttreatment IELT increase compared with the 30 mg dapoxetine (P < 0.05) and paroxetine (P < 0.01) groups. Dapoxetine (60 mg) 1–3 h before planned intercourse is a very effective treatment modality for PE. However, an on-demand dose of 30 mg dapoxetine is no more effective than the currently prescribed paroxetine treatment.

The role of dapoxetine hydrochloride on-demand for the treatment of men with premature ejaculation

“…Of the remaining 18 references, 11 were excluded after reading the full text. After a quality validation, only seven studies 9 10 11 12 13 14 15 were selected from the literature search. The flow chart of the evidence acquisition process is summarized in Figure 1 , and the methodological quality of the included studies is reported in Figure 2 .…”

Evaluation of dapoxetine treatment success in lifelong premature ejaculation patients with penile sympathetic skin response

“…(Wyllie & Hellstrom, ) Dapoxetine is a new SSRI similar to many stereochemically defined SSRIs (Giuliano & Hellstrom, ). Pharmacological investigations have shown that dapoxetine is a potent inhibitor of the 5‐HT transporter, that its pharmacokinetics are not affected by age, ethnicity or dosing frequency (with doses of 30 and 60 mg) and that “on‐demand” usage is effective (Andersson, Mulhall, & Wyllie, ), making dapoxetine a novel effective treatment modality for PE (Simsek et al., ). The results of several studies show that dapoxetine can improve the symptoms of PE, prolong IELT and increase sexual satisfaction (Simsek et al., ; Russo et al., ).…”

The characterization, current medications, and promising therapeutics targets for premature ejaculation

“…Dapoxetine (30 and 60 mg) has been evaluated on demand in men with PE and ED in five industry-sponsored randomized, double-blind, placebocontrolled studies in 6081 men aged at least 18 years and showed an increase in IELT . High dose (60 mg) dapoxetine taken 1-3 h before intercourse displayed a higher post-treatment IELT increase compared to 30 mg dapoxetine (P < 0.05) and paroxetine (P < 0.01) and can be directly administrated in cases of severe PE (e.g., IELT <30 s; Simsek et al, 2014). However, caution to patients should be advised for 60 mg dose of dapoxetine (McMahon et al, 2013b).…”